Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Sep 25

PMID 39320053

Authors

Michael C Brown

Vincent M DAnniballe

David Boczkowski

Harini Kandadi

Nadeem Sheikh

William Kornahrens Jr

Elisabeth I Heath

Archana Thakur

Wei Chen

Lawrence Lum

Frank C Cackowski

Julie Boerner

Michael D Gunn

Andrew J Armstrong

Smita K Nair

Affiliations

Soon will be listed here.

Abstract

Significance: The identification of factors that determine successful cancer immunotherapy, particularly in refractory tumor types like mCRPC, is urgently needed: both to identify patients that may benefit from such therapies and to uncover routes to sensitize patients with cancer to immunotherapy. Our work links functional peripheral immune responses with race and survival after cellular immunotherapy in men with mCRPC.

References

GuhaThakurta D, Sheikh N, Fan L, Kandadi H, Meagher T, Hall S . Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res. 2015; 21(16):3619-30. PMC: 4868054. DOI: 10.1158/1078-0432.CCR-14-2334. View

Weiner A, Vidotto T, Liu Y, Mendes A, Salles D, Faisal F . Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat Commun. 2021; 12(1):935. PMC: 7876147. DOI: 10.1038/s41467-021-21245-w. View

Cho S, Kim S, Lee Y, Song E, Kim U, Kim H . Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1. J Immunother Cancer. 2020; 8(1). PMC: 7254149. DOI: 10.1136/jitc-2019-000277. View

Wang T, Zhang J, Wang Y, Li Y, Wang L, Yu Y . Influenza-trained mucosal-resident alveolar macrophages confer long-term antitumor immunity in the lungs. Nat Immunol. 2023; 24(3):423-438. DOI: 10.1038/s41590-023-01428-x. View

Quach H, Rotival M, Pothlichet J, Loh Y, Dannemann M, Zidane N . Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. Cell. 2016; 167(3):643-656.e17. PMC: 5075285. DOI: 10.1016/j.cell.2016.09.024. View

Griffiths J, Wallet P, Pflieger L, Stenehjem D, Liu X, Cosgrove P . Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc Natl Acad Sci U S A. 2020; 117(27):16072-16082. PMC: 7355015. DOI: 10.1073/pnas.1918937117. View

Hawley J, Pan S, Kandadi H, Chaimowitz M, Sheikh N, Drake C . Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T. J Natl Cancer Inst. 2021; 114(2):314-317. PMC: 8826456. DOI: 10.1093/jnci/djab145. View

Clark R, Vesprini D, Narod S . The Effect of Age on Prostate Cancer Survival. Cancers (Basel). 2022; 14(17). PMC: 9454626. DOI: 10.3390/cancers14174149. View

Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller L . The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020; 368(6494):973-980. PMC: 7757858. DOI: 10.1126/science.aay9189. View

10.

Round J, Lee S, Li J, Tran G, Jabri B, Chatila T . The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011; 332(6032):974-7. PMC: 3164325. DOI: 10.1126/science.1206095. View

11.

Geller A, Shrestha R, Woeste M, Guo H, Hu X, Ding C . The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nat Commun. 2022; 13(1):759. PMC: 8828725. DOI: 10.1038/s41467-022-28407-4. View

12.

Kantoff P, Higano C, Shore N, Berger E, Small E, Penson D . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5):411-22. DOI: 10.1056/NEJMoa1001294. View

13.

Valero C, Lee M, Hoen D, Weiss K, Kelly D, Adusumilli P . Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021; 12(1):729. PMC: 7851155. DOI: 10.1038/s41467-021-20935-9. View

14.

Heath E, Thakur A, Chen W, Hwang C, Paller C, Cackowski F . Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer. Cancer Res Commun. 2024; 4(7):1715-1725. PMC: 11240276. DOI: 10.1158/2767-9764.CRC-24-0112. View

15.

Antonarakis E, Small E, Petrylak D, Quinn D, Kibel A, Chang N . Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clin Cancer Res. 2018; 24(19):4662-4671. PMC: 6481607. DOI: 10.1158/1078-0432.CCR-18-0638. View

16.

Awasthi S, Berglund A, Abraham-Miranda J, Rounbehler R, Kensler K, Serna A . Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2020; 27(1):320-329. PMC: 8042600. DOI: 10.1158/1078-0432.CCR-20-2925. View

17.

Boukhaled G, Gadalla R, Elsaesser H, Abd-Rabbo D, Quevedo R, Yang S . Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nat Immunol. 2022; 23(8):1273-1283. DOI: 10.1038/s41590-022-01262-7. View

18.

Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P . Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2017; 29(2):377-385. DOI: 10.1093/annonc/mdx742. View

19.

Higano C, Armstrong A, Sartor A, Vogelzang N, Kantoff P, McLeod D . Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 2019; 125(23):4172-4180. PMC: 6856402. DOI: 10.1002/cncr.32445. View

20.

Nedelec Y, Sanz J, Baharian G, Szpiech Z, Pacis A, Dumaine A . Genetic Ancestry and Natural Selection Drive Population Differences in Immune Responses to Pathogens. Cell. 2016; 167(3):657-669.e21. DOI: 10.1016/j.cell.2016.09.025. View